An update and future directions in advanced gastric or gastrointestinal junction cancer (G/GEJC)

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2022年 / 15卷 / SUPPL 6期
关键词：
OPEN-LABEL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 112
页数：4
相关论文
共 50 条
  • [31] An update on male breast cancer and future directions for research and treatment
    Berta, Sousa
    Elizabeth, Moser
    Fatiman, Cardoso
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 717 (1-3) : 71 - 83
  • [32] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [33] Advanced Prostate Cancer: Treatment Advances and Future Directions
    Swami, Umang
    McFarland, Taylor R.
    Nussenzveig, Roberto
    Agarwal, Neeraj
    TRENDS IN CANCER, 2020, 6 (08): : 702 - 715
  • [34] Radiotheranostics in advanced prostate cancer: Current and future directions
    Jia, Angela Y. Y.
    Kiess, Ana P.
    Li, Qiubai
    Antonarakis, Emmanuel S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (01) : 11 - 21
  • [35] Current treatment and future directions for advanced pancreatic cancer
    Rothenberg, ML
    PANCREATIC CANCER: ADVANCES IN MOLECULAR PATHOLOGY, DIAGNOSIS & CLINICAL MANAGEMENT, 1998, : 157 - 164
  • [36] Future directions in endocrine treatment of advanced breast cancer
    Bland, KI
    ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (08) : 14S - 16S
  • [37] Radiotheranostics in advanced prostate cancer: Current and future directions
    Angela Y. Jia
    Ana P. Kiess
    Qiubai Li
    Emmanuel S. Antonarakis
    Prostate Cancer and Prostatic Diseases, 2024, 27 : 11 - 21
  • [38] Oxaliplatin for the treatment of advanced colorectal cancer: Future directions
    Ducreux, M
    Louvet, C
    Bekradda, M
    Cvitkovic, E
    SEMINARS IN ONCOLOGY, 1998, 25 (02) : 47 - 53
  • [39] Current and future directions for the treatment of advanced thyroid cancer
    Prasongsook, Naiyarat
    ANNALS OF ONCOLOGY, 2019, 30 : 70 - 70
  • [40] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345